Subscribe to Updates in Healthcare

RSS By Email

RSS By RSS

Add to Google Reader or Homepage

Subscribe in Bloglines


The Expertise Imperative and Compliance Technology
Access to a diverse array of specialized expert inputs drives superior decisions in every organizational context: within corporations, by investors and consultancies, and within nonprofits. When decision makers are confident of their decision inputs, they can respond more quickly and creatively to challenges and opportunities.Learn more about GLG's Compliance Framework


This page may include content provided by Council Members, your access to which is subject to the Terms of Use.
Find Out More

GLG News by SSRI Prescribers (US)

Articles with lock require a subscription to GLG News | Request a free trial
November 24, 2008
Gardasil will most certainly be approved for boys
Analysis of: Gardasil, Merck's Cervical Cancer Vaccine, Demonstrated Efficacy in Preventing HPV-Related Disease in Males in Phase III Study | www.fiercebiotech.com
Author: GLG Expert Contributor
This study reveals the nature of the disease- it affects both men and women.   This study confirms the benefit of use of Gardasil in boys and men.   
November 24, 2008
Efficacy isn't everything
Analysis of: 2nd Generation Antidepressants Prove Effective | health.usnews.com
Author: GLG Expert Contributor
This article tells you only that the drugs are equally effective, but not what that really means in real life.
Daniel WynnNovember 17, 2008
"Tamper-Proof" -- A Significant Gain to Whom??
Analysis of: FDA Asks if Pain Pill Is Tamper-Proof | online.wsj.com
Author: Daniel Wynn, Director, Clinical Research, Consultants In Neurology Ltd.
Abuse resistant long acting narcotics offer benefit as they are less desirable to those who might wish a quick high via snorting, injecting crushed time-release narcotic. Unfortunately, given the higher cost than long acting generics and increased pressure on physicians to prescribe generics, expect...
Louis SanfilippoNovember 10, 2008
Astra Zeneca Seeking to Widen Indications, Markets for Seroquel XR
Analysis of: AstraZeneca Announces European SEROQUEL XR Submission for the Treatment of Generalised Anxiety Disorder | www.pharmalive.com
Author: Louis Sanfilippo, President, LCS Group, LLC
Astra Zeneca is pursuing important medical and, of course, commercial goals by seeking the expanded clinical indications of major depression and generalized anxiety disorder for Seroquel XR, heir to blockbuster Seroquel (quetiapine).  This latest EU submission culminates regulatory submissions...
November 3, 2008
UCB's Vimpat (lacosamide) receives FDA approval
Analysis of: UCB's Vimpat(R) approved by U.S. FDA as adjunctive therapy for partial onset seizures in adults | www.pipelinereview.com
Author: GLG Expert Contributor
FDA has approved lacosamide for add-on therapy of partial onset seizures.  It will be marketed by UCB under the brand name Vimpat.
October 13, 2008
Just because they say so, it ain't necessarily so.....
Analysis of: St John's Wort 'as good as Prozac' | ukpress.google.com
Author: GLG Expert Contributor
This "report" tells you nothing that you need to know in order to assess the validity of these studies.  We have always known that St. John's Wort has some effectiveness---but it certainly does not come without side-effects.  Where is the information about the length of the studies, the relative...
October 8, 2008
Interesting, but be cautious
Analysis of: Lilly Announces Initiation of Second Global Phase III Trial of Investigational Alzheimer's Disease Compound | newsroom.lilly.com
Author: GLG Expert Contributor
Gamma secretase inhibitors are one of several kinds of drugs being studied for the prevention/amelioration of Alzheimer's.  In concept they make sense.
September 11, 2008
Psychotherapy may save money
Analysis of: National Trends in Psychotherapy by Office-Based Psychiatrists | archpsyc.ama-assn.org
Author: GLG Expert Contributor
Unfortunately, many insurance payors do not realize that allowing psychotherapy visits may save the money in the long run by reducing the need for much more costly Inpatient psychiatric treatment. I find that my patients who receive psychotherapy are much less likely to miss work and much...
September 1, 2008
The Devil Is in the Details
Analysis of: ADAGIO Trial Results Show Teva's AZILECT(R) 1 Mg Tablets Slow Progression Of Parkinson's Disease | www.medicalnewstoday.com
Author: GLG Expert Contributor
This large study shows that PD patients' severity of motor dysfunction is better on rasagiline than on placebo.
August 6, 2008
Concerns about the Rember Phase 2 data
Analysis of: New Treatment Halts Progress of Alzheimer's Disease | www.abdn.ac.uk
Author: GLG Expert Contributor
While the clinical trial data remain unpublished, those who attended the ICAD conference remain concerned about the possibility that the effects are not as pronounced as the interpretation by the investigators.

Page : 1 2 3 4 5 6 7 8 9 10 Next1 to 10 of 571

More GLG News in
Healthcare

Most Popular:
Source Article | Expert Analyses
 

GLG News: What Experts Think Is Important





Analytics


Generated at 2008-12-01T21:45:56.203